Jupiter Neurosciences, Inc. Common Stock Net Assets
Jupiter Neurosciences, Inc. Common Stock net assets. Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has net assets worth $-365.97K USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.72 Million) and total liabilities ($4.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore JUNS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-365.97K |
| % of Total Assets | -9.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Net assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Jupiter Neurosciences, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual net assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. For live market cap and overall valuation, see Jupiter Neurosciences, Inc. Common Stock (JUNS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.83 Million | -143.91% |
| 2024-12-31 | $4.17 Million | +171.91% |
| 2023-12-31 | $-5.80 Million | +18.80% |
| 2022-12-31 | $-7.14 Million | -37.98% |
| 2021-12-31 | $-5.18 Million | -39.52% |
| 2020-12-31 | $-3.71 Million | +26.02% |
| 2019-12-31 | $-5.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jupiter Neurosciences, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2668074900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Jupiter Neurosciences, Inc. Common Stock Net Assets Breakdown (December 2025)
Jupiter Neurosciences, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.44K | % |
| Other Components | $32.83 Million | % |
| Total Equity | $-1.83 Million | 100.00% |
Jupiter Neurosciences, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
STS Global Income & Growth Trust PLC
LSE:STS
|
$3.20 Million |
|
METALQUEST MINING INC.
F:E7Q
|
$3.21 Million |
|
Magnetic North Acquisition Corp
V:MNC
|
$3.21 Million |
|
Omnia Metals Group Ltd
AU:OM1
|
$3.21 Million |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
$3.20 Million |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
$3.20 Million |
|
Madhucon Projects Limited
NSE:MADHUCON
|
$3.20 Million |
|
EQTEC plc
LSE:EQT
|
$3.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jupiter Neurosciences, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,172,008 to -1,831,852, a change of -6,003,860 (-143.9%).
- Net loss of 8,644,897 reduced equity.
- Other factors increased equity by 2,641,037.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.64 Million | -471.92% |
| Other Changes | $2.64 Million | +144.17% |
| Total Change | $- | -143.91% |
Book Value vs Market Value Analysis
This analysis compares Jupiter Neurosciences, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-43.05 | $2.43 | x |
| 2020-12-31 | $-31.85 | $2.43 | x |
| 2021-12-31 | $-40.93 | $2.43 | x |
| 2022-12-31 | $-16.30 | $2.43 | x |
| 2023-12-31 | $-13.23 | $2.43 | x |
| 2024-12-31 | $10.87 | $2.43 | x |
| 2025-12-31 | $-3.97 | $2.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jupiter Neurosciences, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39662.77%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-8.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.55 Million |
| 2020 | 0.00% | -146.92% | 2.05x | 0.00x | $-1.28 Million |
| 2021 | 0.00% | -686.39% | 0.96x | 0.00x | $-3.86 Million |
| 2022 | 0.00% | -2125.15% | 0.99x | 0.00x | $-4.24 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.20 Million |
| 2024 | -58.48% | 0.00% | 0.00x | 1.49x | $-2.86 Million |
| 2025 | 0.00% | -39662.77% | 0.00x | 0.00x | $-8.46 Million |
Industry Comparison
This section compares Jupiter Neurosciences, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jupiter Neurosciences, Inc. Common Stock (JUNS) | $-365.97K | 0.00% | N/A | $3.20 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more